WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Nadav Kidron Biography and Net Worth

CEO of Oramed Pharmaceuticals

Mr. Kidron serves as Chief Executive Officer & Director of Oramed Pharmaceuticals, which he co-founded in 2006.

Mr. Kidron is an entrepreneur whose experience includes senior executive roles in a wide range of industries.

He co-founded Entera Bio as a joint venture formed by Oramed and DNA Biomedical Solutions. He is a member of the IATI Board, and an international lecturer on Israel’s entrepreneurial culture and the country’s roots as an oasis of innovative ideas.

He holds a bachelor’s degree in law and an international master’s in business administration, both from Bar-Ilan University in Israel. Mr. Kidron is a fellow of the Merage Business Executive Leadership Program and a member of the Israeli Bar Association.

What is Nadav Kidron's net worth?: The estimated net worth of Nadav Kidron is at least $298,620.00 as of March 16th, 2023. Mr. Kidron owns 126,000 shares of Oramed Pharmaceuticals stock worth more than $298,620 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Kidron may own. Additionally, Mr. Kidron receives an annual salary of $754,300.00 as CEO at Oramed Pharmaceuticals. Learn More about Nadav Kidron's net worth.
How old is Nadav Kidron?: Mr. Kidron is currently 50 years old. There are 2 older executives and no younger executives at Oramed Pharmaceuticals. Learn More on Nadav Kidron's age.
What is Nadav Kidron's salary?: As the CEO of Oramed Pharmaceuticals Inc., Mr. Kidron earns $754,300.00 per year. Learn More on Nadav Kidron's salary.
How do I contact Nadav Kidron?: The corporate mailing address for Mr. Kidron and other Oramed Pharmaceuticals executives is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. Oramed Pharmaceuticals can also be reached via phone at (844) 967-2633 and via email at [email protected]. Learn More on Nadav Kidron's contact information.
Has Nadav Kidron been buying or selling shares of Oramed Pharmaceuticals?: Nadav Kidron has not been actively trading shares of Oramed Pharmaceuticals during the past quarter. Most recently, on Thursday, March 16th, Nadav Kidron bought 26,000 shares of Oramed Pharmaceuticals stock. The stock was acquired at an average cost of $2.04 per share, with a total value of $53,040.00. Following the completion of the transaction, the chief executive officer now directly owns 126,000 shares of the company's stock, valued at $257,040. Learn More on Nadav Kidron's trading history.
Who are Oramed Pharmaceuticals' active insiders?: Oramed Pharmaceuticals' insider roster includes Nadav Kidron (CEO), and Kevin Rakin (Director). Learn More on Oramed Pharmaceuticals' active insiders.

Nadav Kidron Insider Trading History at Oramed Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/16/2023	Buy	26,000	$2.04	$53,040.00	126,000
3/14/2023	Buy	100,000	$2.01	$201,000.00	100,000
8/9/2021	Sell	220,000	$20.11	$4,424,200.00	648,573
7/10/2018	Sell	61	$5.98	$364.78	958,087
5/12/2016	Buy	1,000	$6.95	$6,950.00	957,448
3/19/2015	Buy	2,600	$3.88	$10,088.00

Nadav Kidron Buying and Selling Activity at Oramed Pharmaceuticals

Oramed Pharmaceuticals Company Overview

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Today's Range

Now: $2.37

$2.37

$2.49

50 Day Range

MA: $2.37

$2.17

$2.52

2 Week Range

Now: $2.37

$2.00

$3.67

Volume

100,535 shs

Average Volume

139,352 shs

Market Capitalization

$95.54 million

P/E Ratio

21.55

Dividend Yield

N/A

Beta

1.7

WARNING: “Buffett Indicator” flashing for first time in 50 years

From Behind the Markets | Ad